- Home
- NUVL vs GSAT Comparison
NUVL vs GSAT Comparison
Compare NUVL & GSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GSAT
- Stock Information
- Founded
- NUVL 2017
- GSAT 2003
- Country
- NUVL United States
- GSAT United States
- Employees
- NUVL N/A
- GSAT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GSAT Telecommunications Equipment
- Sector
- NUVL Health Care
- GSAT Consumer Discretionary
- Exchange
- NUVL Nasdaq
- GSAT Nasdaq
- Market Cap
- NUVL 6.5B
- GSAT 5.7B
- IPO Year
- NUVL 2021
- GSAT 2006
- Fundamental
- Price
- NUVL $98.17
- GSAT $50.78
- Analyst Decision
- NUVL Strong Buy
- GSAT Strong Buy
- Analyst Count
- NUVL 11
- GSAT 4
- Target Price
- NUVL $121.45
- GSAT $49.00
- AVG Volume (30 Days)
- NUVL 527.5K
- GSAT 1.4M
- Earning Date
- NUVL 10-30-2025
- GSAT 11-06-2025
- Dividend Yield
- NUVL N/A
- GSAT N/A
- EPS Growth
- NUVL N/A
- GSAT N/A
- EPS
- NUVL N/A
- GSAT N/A
- Revenue
- NUVL N/A
- GSAT $260,664,000.00
- Revenue This Year
- NUVL N/A
- GSAT $7.93
- Revenue Next Year
- NUVL N/A
- GSAT $11.32
- P/E Ratio
- NUVL N/A
- GSAT N/A
- Revenue Growth
- NUVL N/A
- GSAT 14.85
- 52 Week Low
- NUVL $55.54
- GSAT $15.45
- 52 Week High
- NUVL $104.90
- GSAT $54.57
- Technical
- Relative Strength Index (RSI)
- NUVL 60.96
- GSAT 68.05
- Support Level
- NUVL $90.00
- GSAT $41.06
- Resistance Level
- NUVL $99.94
- GSAT $46.39
- Average True Range (ATR)
- NUVL 5.06
- GSAT 3.38
- MACD
- NUVL 0.69
- GSAT -0.20
- Stochastic Oscillator
- NUVL 66.81
- GSAT 73.06
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GSAT Globalstar Inc.
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.